Login / Signup

Immune Status and SARS-CoV-2 Viral Dynamics.

Yijia LiCarlee B MoserEvgenia AgaJudith S CurrierDavid Alain WohlEric S DaarJustin RitzAlexander L GreningerScott SiegUrvi M ParikhRobert W CoombsMichael D HughesJoseph J EronDavey M SmithKara W ChewJonathan Z Linull null
Published in: The Journal of infectious diseases (2023)
Immunocompromised individuals are disproportionately affected by severe coronavirus disease 2019, but immune compromise is heterogenous, and viral dynamics may vary by the degree of immunosuppression. In this study, we categorized ACTIV-2/A5401 participants based on the extent of immunocompromise into none, mild, moderate, and severe immunocompromise. Moderate/severe immunocompromise was associated with higher nasal viral load at enrollment (adjusted difference in means: 0.47 95% confidence interval, .12-.83 log10 copies/mL) and showed a trend toward higher cumulative nasal RNA levels and plasma viremia compared to nonimmunocompromised individuals. Immunosuppression leads to greater viral shedding and altered severe acute respiratory syndrome coronavirus 2 viral decay kinetics. Clinical Trials Registration. NCT04518410.
Keyphrases
  • sars cov
  • respiratory syndrome coronavirus
  • coronavirus disease
  • clinical trial
  • early onset
  • high intensity
  • chronic rhinosinusitis
  • drug induced
  • study protocol